Abstract
AbstractBackgroundComorbidity, especially cardiovascular disease, is frequent in people with dementia. At the same time, access to healthcare professionals and appropriate treatment might be more difficult to obtain. We used the Austrian prescription claims database to analyse the treatment of common comorbidities in patients with dementia and controls.MethodsInsurance claims data covering 98% of the Austrian population were used. We identified patients treated with one of the four approved antidementives (Rivastigmine, Galantamine, Donepezil, Memantine) in the period of 2005‐16, and extracted age‐ and sex‐matched controls that were not being treated with an antidementive. Total number of medication was recorded and odds ratios (OR) for being prescribed that specific medication were calculated separately for the most common classes.ResultsWe identified 127896 patients treated with an antidementive and matched them to controls in a 1:1 fashion. The median age was 82.3 (IQR 76.7 ‐ 86.6) and 65% were female. Those treated with an antidementive were prescribed significantly fewer drugs in total, including the antidementive drug, compared to controls (median 8 [IQR 5 ‐ 11] vs 9 [5 ‐ 15], p < 0.001, Table 1). The odds of receiving any of the recorded somatic comedication were significantly lower in patients treated with antidementives, with OR ranging from 0.96 for antidiabetics to 0.5 for antihypertensive and 0.34 for anti inflammatory drugs. Conversely, the odds for treatment with psychiatric drugs were significantly higher in this group, with an OR for antidepressants of 1.8 and 4 for antipsychotic drugs (Figure 1).ConclusionPatients treated with antidementives are less likely to receive treatment for common somatic comorbidities and more likely to receive treatment for psychiatric comorbidities than age and sex‐matched controls. Since available data overwhelmingly suggests that patients with dementia suffer from more comorbidities than those without, this data can be interpreted as evidence for undertreatment of somatic comorbidities in this patient group. with dementia and controls. Additionally, usage of antipsychotic was very frequent and exceeded previously published numbers, emphasizing the need for integrated care for patients with dementia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.